local_hospital

Azienda Ospedaliero Universitaria Di Modena

Address
lock Available on a paid plan

Respiratory and Infectious Diseases

At Azienda Ospedaliero Universitaria Di Modena, research in Respiratory Tract Diseases and Virus Diseases focuses on conditions such as chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, asthma, bronchiectasis, and post-acute COVID syndrome. These studies are designed to better understand disease progression and evaluate new treatment strategies for people with complex lung and infectious diseases.

  • Chronic lung disease, including COPD, bronchiectasis, and progressive pulmonary fibrosis
  • Severe respiratory conditions such as idiopathic pulmonary fibrosis and acute respiratory distress syndrome
  • Infectious disease research covering HIV, hepatitis B, fungal infections, and recurrent Clostridioides difficile infection
  • Trials aiming to improve symptom control, reduce complications, and assess treatment effectiveness

The site also contributes to studies in immune system diseases linked to respiratory inflammation and infection-related complications.

Oncology Across Solid Tumors

A major part of the trial portfolio at this hospital in Modena is devoted to Neoplasms, with a strong emphasis on breast cancer, lung cancer, gastrointestinal cancers, ovarian cancer, and pancreatic cancer. The research is centered on testing new therapies, improving outcomes after standard treatment, and finding better ways to delay recurrence or spread.

  • Breast cancer, including HER2-positive, HER2-negative, triple-negative, and hormone receptor-positive disease
  • Lung cancer studies spanning non-small cell and small cell disease
  • Gastric, colorectal, pancreatic, and head and neck cancers
  • Studies evaluating new combinations, maintenance approaches, and post-surgery treatment strategies

Many of these trials explore whether emerging cancer therapies can improve survival or extend the time before disease progression.

Hematology, Blood Disorders, and Cellular Therapy

The research program includes extensive work in Hemic and Lymphatic Diseases, especially acute leukemias, chronic lymphocytic leukemia, lymphomas, multiple myeloma, and inherited or acquired blood disorders. These studies are aimed at refining treatment choices, supporting deeper disease control, and improving long-term outcomes for patients with difficult-to-treat hematologic conditions.

  • Acute myeloid leukemia, acute lymphoblastic leukemia, and chronic myeloid leukemia
  • Chronic lymphocytic leukemia, diffuse large B-cell lymphoma, mantle cell lymphoma, and marginal zone lymphoma
  • Multiple myeloma and other plasma cell disorders
  • Blood-related conditions such as sickle cell disease, thalassemia, and thrombocytopenia

This area includes trials testing new drug combinations and strategies to reduce relapse risk and improve disease response.

Autoimmune, Inflammatory, and Kidney Diseases

Research in Immune System Diseases, Skin and Connective Tissue Diseases, and kidney disorders addresses illnesses such as systemic lupus erythematosus, systemic sclerosis, ulcerative colitis, IgA nephropathy, and lupus nephritis. The goal is to evaluate treatments that can better control inflammation, protect organ function, and reduce long-term complications.

  • Autoimmune diseases affecting the kidneys, joints, skin, and internal organs
  • Inflammatory bowel disease, including ulcerative colitis
  • Renal conditions such as IgA nephropathy, chronic kidney disease, and end-stage kidney disease
  • Trials focused on symptom relief, disease control, and preservation of kidney function

The site also studies hidradenitis suppurativa, psoriasis, and other chronic inflammatory skin conditions.

Neurology and Neurodegenerative Research

A notable part of the portfolio covers Nervous System Diseases and neurodegenerative disorders, including multiple sclerosis, Alzheimer’s disease, amyotrophic lateral sclerosis, Parkinson’s disease, and epilepsy. These trials are intended to test new therapies, improve symptom management, and slow disease progression in conditions that can strongly affect daily life.

  • Multiple sclerosis and relapsing inflammatory neurological disease
  • Alzheimer’s disease, frontotemporal dementia, and related cognitive disorders
  • Amyotrophic lateral sclerosis and other progressive neurodegenerative illnesses
  • Headache, migraine, and refractory epilepsy research

Research in this area often aims to preserve function, reduce relapses, and improve quality of life over time.

Cardiovascular, Metabolic, and Liver Health

The site also conducts studies in Cardiovascular Diseases, Nutritional and Metabolic Diseases, and Digestive System Diseases. Key topics include atherosclerotic cardiovascular disease, hypertension, atrial fibrillation, metabolic dysfunction-associated steatohepatitis, and primary biliary cholangitis. These trials are focused on prevention, risk reduction, and better long-term disease management.

  • Heart and vascular disease, including elevated cardiovascular risk and atrial fibrillation
  • Liver and biliary disorders such as MASH/NASH, primary biliary cholangitis, and chronic hepatitis B
  • Metabolic conditions including severe hypertriglyceridemia and obesity-related disease
  • Studies evaluating whether new treatments can reduce complications and improve clinical outcomes

This research reflects a broad interest in preventing major organ damage and improving chronic disease control.

Pediatric, Rare, and Specialized Conditions

Beyond the major disease groups, Azienda Ospedaliero Universitaria Di Modena participates in trials for rare diseases, congenital disorders, and selected pediatric conditions. Examples include Langerhans cell histiocytosis, Prader-Willi syndrome, generalized epidermolysis bullosa simplex, and congenital adrenal hyperplasia. These studies aim to improve diagnosis, refine treatment options, and address unmet needs in less common diseases.

  • Rare inherited and developmental disorders
  • Pediatric hematology and oncology, including leukemia and neuroblastoma
  • Specialized reproductive and pregnancy-related research
  • Trials designed to generate better care options where standard treatments are limited

The breadth of this work shows a strong commitment to both common and uncommon conditions across the clinical spectrum.

Site Overview

assignment
349
connected trials
corporate_fare
161
sponsors
science
496
IMPs

Activity Indicator

Last 6 months

32
Trials started
-20% vs previous period.
40
Trials started 6–12 months ago
349
Total trials linked
Highly Active
trending_downDeclining-20%
4
7
7
7
5
2
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 4 of 24 therapeutic areas and 15 of 496 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 447 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
188
Sponsors (total)
161
Active sponsors
110

Sponsor Network

Top 110 by active trials.

lock +109 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +61 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 566 other sites in Italy

description
Trial volume
349
Outperforms 96% of sites
public
Therapeutic diversity
25areas
Outperforms 97% of sites
groups
Sponsor diversity
161sponsors
Outperforms 97% of sites

Therapeutic Area Benchmark — Italy

Select a therapeutic area to compare against other sites in Italy.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Italy

Market Share

Country: Italy

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Azienda Ospedaliero Universitaria Di Modena

lock Showing 1 of 349 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
"APalutamide and stEReotactic body radiation therapy for low burden metastatic hormone senSItive prostate cancer, a rANdomized trial -PERSIAN".Fondazione Radioterapia Oncologica OnlusPhase IIRecruitingMar 2023

IMP list

lock Showing 1 of 496 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Pembrolizumab27Unknown2017-06-082025-12-15

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.